CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Qatar Condemns Drone Strike as Iran Conflict Threatens Gulf Shipping and Global Markets 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
Arcadia Mayor Eileen Wang Pleads Guilty in China Foreign Agent Case 
Iran Military Readiness Intensifies After Meeting With Mojtaba Khamenei 
Trump Weighs Renewed Military Action Against Iran Amid Strait of Hormuz Crisis 
Trump Administration’s National Science Board Dismissal Sparks Warning From Scientists 
Trump-Xi Summit Sparks Renewed Hope for Americans Detained in China 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
